Hospital financial implications of subcutaneous versus intravenous trastuzumab plus pertuzumab in Japan: a micro-costing and threshold analysis
This study demonstrates that in Japan, switching trastuzumab plus pertuzumab from intravenous to subcutaneous administration improves hospital financial outcomes by significantly reducing material and labor costs, which outweighs the lower outpatient management fee revenue.